744497
Last Update Posted: 2016-10-17
This data has been translated from it's original language using AI, and may contain errors. Please change your language to view the original data.
Recruiting has ended
Males accepted | 18 Years + |
1930 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Randomisert studie som sammenligner Docetaxel pluss Dasatinib med Docetaxel pluss placebo hos pasienter med kastrasjonsresistent prostatakreft.
Formålet med denne studien er å avgjøre om overlevelsen kan forlenges hos pasienter med kastrasjonsresistent prostatakreft som mottar dasatinib sammen med docetaxel og prednison.
Eligibility
Relevant conditions:
Prostatakreft
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov